Dr Reddy's Laboratories
Pharma sector outlook 2019 in India: Expect big recovery in New Year; IPCA, Divis Lab champions of 2018
Mon, Dec 31, 2018
The sector has been volatile throughout the year due to constant news flow in the markets. Some giants of the sector witnessed objections over their manufacturing plants and medicine pricing in the U.S. markets.
More >
Big blow to Dr Reddy's over opioid addiction treatment block in US; share price tanks a whopping 11%
Mon, Jul 16, 2018
Analysts at Jefferies believe injunction is a negative surprise for Dr Reddy’s and risks for FY20-22 EPS estimates have increased after the ruling. retain “underperform”, cuts TP to 1,850 rupees from 1,910 rupees
More >
Dr Reddy's last day on Sensex; stock rallies 20% in 8 sessions
Fri, Jun 15, 2018
Dr Reddy's share price gained as much as 20 per cent in the last 8 sessions, thanks to a renewed optimism on the sector. Nifty Pharma index itself gained 14 per cent during the same period. In Friday's trade, Nifty Pharma was the top sectoral gainer, led by gains in Dr Reddy's.
More >
Dr Reddy's Q4 net profit rises by 319%
Fri, May 12, 2017
GV Prasad, Co-Chairman and CEO of Dr Reddy's Laboratories said, “FY17 has been challenging year due to lack of new product approvals for the US market. However, our other geoghraphies delivered good performance with several new product launches.”
More >
Q3FY17: Dr Reddy's Laboratories' net profit down 19% at Rs 470 crore
Sat, Feb 04, 2017
GV Prasad, Co-chairman of Dr Reddy's Laboratories said, "Our performance in Q3 has delivered a modest sequential revenue growth of 3% over the previous quarter. Our EBITDA has improved significantly from the last quarter to Rs 8.8 billion, on the back of enhanced emphasis on operational efficiencies and controlling of SG&A cost across all our business."
More >
Pharma stocks fall sharply as US drug pricing investigation nears completion
Fri, Nov 04, 2016
Media reports suggest that the US Congress investigation into price hikes, that began in October 2014, may be nearing completion, culminating into charges of price collusion against companies / individuals by the year end.
More >
Dr Reddy gets listed on Dow Jones sustainability indices 2016
Tue, Sep 13, 2016
G V Prasad, Co-chairman and CEO of Dr Reddy's Laboratories said,” This listing has earned us the trust and respect of all stakeholders we serve. I see our inclusion in the Dow Jones indices as another validation of our commitment to sustainability in all aspects of our business.”
More >
Sun, Dr Reddy's, Glenmark strengthen their US play
Mon, Jul 18, 2016
Domestic pharma players are in stiff competition in US market. Sun Pharma with its taking over of SPARC's ELEPSIA XR, while Dr. Reddy launching Omeprazole and Sodium bicarbonate capsules and that of Glenmark waiting for 62 ANDA's approval, plans to strenghthen their position in the US.
More >
